targeting ror1 and a two-drug approach to cure cll
Published 7 years ago • 1.9K plays • Length 5:30Download video MP4
Download video MP3
Similar videos
-
1:04
new therapeutic targets in cll: ror1
-
1:37
the rationale behind targeting ror1 in cll and mcl
-
1:29
nvg-111, a ror1 targeting bispecific tce, in r/r cll and mcl: a proof of concept phase i study
-
1:13
dual-targeted regimens for the treatment of cll: anti-cd20 antibodies, btki, and bcl2i
-
2:36
treatment approaches to cll with high-risk molecular features
-
2:34
the impact of gene mutations on prognosis in cll
-
2:39
the safety and efficacy of ibrutinib for the treatment of cll
-
2:46
welcome to blood talks
-
2:40
ror1 signaling & its potential as a therapeutic target for leukemia
-
4:48
exciting insights into the role of ror1 in cll
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
0:59
developing lsc-targeting agents in aml: progress and current therapeutic capacity
-
4:17
how to approach r/r cll
-
2:45
the value of axi-cel as a second-line treatment in r/r lbcl
-
1:31
novel approaches to cll treatment
-
2:51
key btk inhibitor trials for the initial treatment of cll
-
1:04
defining high-risk cll: known and emerging mutations
-
2:49
insights into the role of novel btkis in the treatment landscape of r/r cll
-
1:30
exciting new agents in cll
-
1:36
selecting the best treatment option in cll
-
17:23
updates in cll: key clinical trials in the frontline and r/r setting, pre-clinical data and mrd
-
2:29
the measurement of molecular biomarkers to aid cll treatment